- 6 July 2016
- Transport / Logistics Services
International delivery company UPS has taken steps to expand its global healthcare specific capabilities in support of clinical trials.
UPS has said that investing in a number of specialised solutions will help pharmaceutical companies as well as clinical investigators move their materials and specimens globally, in particular into and out of complex geographies.
The delivery company added that it has made a number of improvements that are specifically targeted to meet strict clinical trial requirements. These include developing a shipping system for clinical investigator sites, an expansion of the healthcare control tower network, package intercept and re-icing capabilities; and upgraded operations to move temperature-sensitive biological specimens in and out of more than 60 countries more efficiently.
“As innovation in the biopharma industry evolves — and with the emergence of personalized therapies and growing direct-to-patient trends — research and development activity will only increase around the world. Our cost-effective portfolio streamlines logistics for clinical trials into one global network across sometimes remote, hard-to-reach locations,” said Habib N’Konou, UPS senior operations director for clinical trials.
“With drug research taking years at a cost in the billions, a product loss or damage, including falling out of temperature range, could mean a costly setback. Our recent improvements to our network will reduce product loss or damage.”
UPS is known to carry 2% of all the world’s goods. Meeting highly specialist clients’ requirements is one of the ways that it can add value to its offering. With biotech industries being at least as valuable as IT in terms of turnover and investment, UPS expansion within this field will meet a lot of valuable customers’ needs.